DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Gaucher Disease Type III - Pipeline Review, H2 2016" report to their offering.
Gaucher disease type III also known as chronic neuronopathic Gaucher disease (subacute form of neuronopathic Gaucher disease). Symptoms include mental deterioration, ataxia, and myoclonic seizures. The cause of Gaucher disease III is the accumulation of a fatty material called glucocerebroside (also known as glucosylceramide) Treatment includes enzyme replacement therapy.
This report provides comprehensive information on the therapeutic development for Gaucher Disease Type III, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher Disease Type III and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Gaucher Disease Type III Overview
- Therapeutics Development
- Pipeline Products for Gaucher Disease Type III - Overview
- Pipeline Products for Gaucher Disease Type III - Comparative Analysis
- Gaucher Disease Type III - Therapeutics under Development by Companies
- Gaucher Disease Type III - Therapeutics under Investigation by Universities/Institutes
- Gaucher Disease Type III - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Gaucher Disease Type III - Products under Development by Companies
- Gaucher Disease Type III - Products under Investigation by Universities/Institutes
Gaucher Disease Type III - Companies Involved in Therapeutics
- Actelion Ltd
- Belrose Pharma Inc
- Erad Therapeutics Inc
- Genzyme Corp
For more information about this report visit http://www.researchandmarkets.com/research/znrcbf/gaucher_disease